Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02696967 · ClinicalTrials.gov registry record · Phase 2
A Study of CLR325 in Chronic Stable Heart Failure Patients.
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 26
- Enrollment target
NCT02696967 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 26 participants.
The verdict
NCT02696967, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 26 participants
- Enrollment target
Study Summary
The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.
Interventions
- OTHER Placebo
- DRUG CLR325
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 26 participants |
| Start Date | 2016-05-17 |
| Est. Completion | 2019-01-14 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02696967
The ClinicalTrials.gov registry entry for NCT02696967 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 26 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT02696967 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02696967 about?
NCT02696967 is a clinical study titled "A Study of CLR325 in Chronic Stable Heart Failure Patients.". The purpose of this study was to determine the safety and tolerability of CLR325 intravenous (i.v.) infusion in patients with stable heart failure to determine if further clinical development of the drug in this indication was warranted.
What is the current status of trial NCT02696967?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 26 participants. The study started on 2016-05-17. Estimated completion is 2019-01-14.
What interventions are being tested in trial NCT02696967?
The interventions under investigation include: Placebo (OTHER), CLR325 (DRUG).
Who is sponsoring clinical trial NCT02696967?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.